Floatz logo

Polio/Rhinovirus Recombinant

Non-muscle-invasive Bladder Cancer

Istari Oncology, Inc.Phase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Non-muscle-invasive Bladder Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3B
Bacillus Calmette-Guerin
Merck Sharp & Dohme LLC
Phase 3B
Tyra-300
Tyra Biosciences, Inc
Phase 1/2CCC

Same molecule, other indications

Polio/Rhinovirus Recombinant is also rated in:

malignant gliomaDormant
B
Indicative ·
58 / 100
View asset →
brain neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →